In addition, and particularly in light of the ivabradine data ... and persisting symptoms (New York Heart Association class II–IV) despite treatment with an evidence-based dose of β-blocker ...

Patients were informed of the investigational nature of the protocol and the limitations of the alternative therapeutic approaches. The initial dose of ivabradine was 5 mg twice a day. After the ...